

Cabaletta Bio™



Gwendolyn Binder, Ph.D.

*Executive Vice President, Science & Technology
(effective February 1, 2019)*

Dr. Binder has more than 17 years of industry and academic leadership experience in translational research and development, T cell manufacturing and the early development of first-in-human engineered T cell therapies. Most recently, Dr. Binder served as Chief Technology Officer at Adaptimmune, where she established manufacturing, compliance, regulatory and clinical operations to lead the transfer of certain T cell receptor (TCR) clinical programs from the Translational Research Program at Penn, now known as the Center for Cellular Immunotherapy (CCI). Dr. Binder then led Adaptimmune's early internal manufacturing and process development teams for vector and cell manufacturing and assembled the company's translational research team. She also established and executed the strategic plan for the company's currently operational GMP facility and built the initial manufacturing and quality team. She went on to lead the company's approximately 150-person research organization. Prior to Adaptimmune, Dr. Binder was the Director of Translational Research Operations at the University of Pennsylvania, working with Dr. Carl June to further advance the Translational Research Program. There, she oversaw the opening of multiple INDs for novel engineered T cell therapy products, including several TCR studies. Prior to that, she was the Director of Scientific Affairs at VIRxSYS Corporation, where she played a key role in enabling the first lentiviral vector IND.

Dr. Binder earned her Ph.D. from the Johns Hopkins University in Cellular and Molecular Medicine, with a focus in viral immunology.